Nonhepatic Cancer in Patients With Liver Cirrhosis: Epidemiology, Treatment Challenges, and Management Strategies
- 1Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
- 2Division of Gastroenterology & Hepatology, Northwestern University, Chicago, Illinois, USA
- 3Section of Hepatology, Rush University Medical Center, Chicago, Illinois, USA .
Abstract
Although the relationship between cirrhosis and hepatocellular carcinoma is well established, a growing body of evidence suggests patients with cirrhosis also face elevated risks of nonhepatic cancers (NHCs). Liver cirrhosis has been found to confer up to a two-fold increased risk for NHCs compared with the general population. Clinicians have limited guidance when treating patients with both NHCs and liver cirrhosis given there is a glaring paucity of data regarding optimal management strategies for this subset of patients. Hepatic dysfunction limits therapeutic and interventional approaches, alters the pharmacokinetics of common anticancer drugs, and increases the risk of side effects associated with anticancer treatment. Patients with well-compensated cirrhosis whose life expectancy is primarily determined by their NHC can be appropriate candidates for anticancer therapy with careful monitoring. Conversely, patients with decompensated cirrhosis should have their clinical focus shift toward managing liver-related complications or transitioning to palliative care because oncological treatment likely worsens overall prognosis. Prognostic models like Child-Pugh and Model for End-Stage Liver Disease scores can be used in a complementary fashion to identify appropriate patients and individualize treatment decisions. In this narrative review, we will examine the epidemiology of NHCs in patients with cirrhosis, the influence of hepatic dysfunction on therapeutic approaches, and the current strength of evidence on the safety and efficacy of common anticancer modalities in the setting of both compensated and decompensated cirrhosis.
Related
- Management of HIV-Associated Cancers in Sub-Saharan Africa: A Scoping Review of Treatment Outcomes, Challenges, and Strategies for Enhancing Care
- Antibiotic Stewardship in Cirrhosis: Current Recommendations and Clinical Challenges
- Beyond conventional treatments: cutting-edge strategies for ascites in cirrhosis
- The Pros & Cons of Measuring Plasma Ammonia in the Management of Patients With Cirrhosis: An ISHEN Debate
- Chain mediating effect of resilience and disease acceptance on social support and self-management behavior in patients with liver cirrhosis
BibTeX
@article{lee2026nonhepatic,
title = {{Nonhepatic Cancer in Patients With Liver Cirrhosis: Epidemiology, Treatment Challenges, and Management Strategies}},
author = {Jonathan S. Lee and Zoë Post and Nancy Reau},
journal = {The American Journal of Gastroenterology},
year = {2026},
month = may,
doi = {10.14309/ajg.0000000000004057},
url = {https://doi.org/10.14309/ajg.0000000000004057},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Nonhepatic Cancer in Patients With Liver Cirrhosis: Epidemiology, Treatment Challenges, and Management Strategies
AU - Jonathan S. Lee
AU - Zoë Post
AU - Nancy Reau
PY - 2026
DA - 2026/05/19
JO - The American Journal of Gastroenterology
DO - 10.14309/ajg.0000000000004057
UR - https://doi.org/10.14309/ajg.0000000000004057
AB - Although the relationship between cirrhosis and hepatocellular carcinoma is well established, a growing body of evidence suggests patients with cirrhosis also face elevated risks of nonhepatic cancers (NHCs). Liver cirrhosis has been found to confer up to a two-fold increased risk for NHCs compared with the general population. Clinicians have limited guidance when treating patients with both NHCs and liver cirrhosis given there is a glaring paucity of data regarding optimal management strategies for this subset of patients. Hepatic dysfunction limits therapeutic and interventional approaches, alters the pharmacokinetics of common anticancer drugs, and increases the risk of side effects associated with anticancer treatment. Patients with well-compensated cirrhosis whose life expectancy is primarily determined by their NHC can be appropriate candidates for anticancer therapy with careful monitoring. Conversely, patients with decompensated cirrhosis should have their clinical focus shift toward managing liver-related complications or transitioning to palliative care because oncological treatment likely worsens overall prognosis. Prognostic models like Child-Pugh and Model for End-Stage Liver Disease scores can be used in a complementary fashion to identify appropriate patients and individualize treatment decisions. In this narrative review, we will examine the epidemiology of NHCs in patients with cirrhosis, the influence of hepatic dysfunction on therapeutic approaches, and the current strength of evidence on the safety and efficacy of common anticancer modalities in the setting of both compensated and decompensated cirrhosis.
SN - 0002-9270
SN - 1572-0241
ER -